54 completed, 12 recruiting, 8 terminated, 7 unknown. 55 Phase 2, 17 Phase 1, 13 Phase 3, 6 Not applicable, 1 Phase 4.
Follow Hemangiosarcoma: new trials by email Literature Review of Hemangiosarcoma trials Research Report on Hemangiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma Vusolimogene Oderparepvec (VO), Pembrolizumab - Angiosarcoma, Angiosarcoma, Adult | Phase 2 | Recruiting | Varun Monga, MBBS | 18 | 2026-01-09 | 2026-09-01 |
| Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE Questionnaire - Cancer, Cystic Carcinomas, Adenoid | Completed | Hospices Civils de Lyon | 62 | 2025-05-23 | 2025-08-06 | |
| Cardiac Angiosarcoma International Registry Cardiac Angiosarcoma | Recruiting | Immune Oncology Research Institute | 500 | 2025-05-01 | 2026-02-18 | |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors AGX101 - Cancer, Advanced Cancer | Phase 1 | Recruiting | Angiex, Inc. | 80 | 2024-07-22 | 2026-09-09 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars Observational - Angiosarcoma | Recruiting | Italian Sarcoma Group | 250 | 2024-03-29 | 2025-11-20 | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A - Angiosarcoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2024-03-22 | 2026-02-13 | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically OMX-0407 - Solid Tumor | Phase 1 / Phase 2 | Terminated | iOmx Therapeutics AG | 68 | 2023-03-30 | 2026-07-24 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| Cemiplimab for Secondary Angiosarcomas Cemiplimab - Secondary Angiosarcoma, Locally Advanced Sarcoma | Phase 2 | Completed | Radboud University Medical Center | 18 | 2022-01-01 | 2024-10-31 |
| Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients Observational Translational Study - Sarcoma, Sarcoma, Leiomyo-, Adult | Recruiting | Royal Marsden NHS Foundation Trust | 800 | 2021-11-19 | 2026-02-25 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study Quality-of-Life Assessment, Sintilimab - Locally Advanced Angiosarcoma, Metastatic Angiosarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-08-23 | 2026-07-21 |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma | Phase 2 | Terminated | Pfizer | 76 | 2021-06-22 | 2024-12-11 |
Showing 20 of 91. Sign in to see all of them.
Sarcoma (63) · Liposarcoma (49) · Leiomyosarcoma (46) · Fibrosarcoma (44) · Histiocytoma, Malignant Fibrous (39) · Sarcoma, Synovial (37) · Neurofibrosarcoma (35) · Hemangiopericytoma, Malignant (23) · Malignant mesenchymal tumor (22) · Rhabdomyosarcoma (22) · Sarcoma, Alveolar Soft Part (18) · Osteosarcoma (17) · Dermatofibrosarcoma (14) · Chondrosarcoma (13)
Neoplasms by Histologic Type (91) · Neoplasms, Connective and Soft Tissue (91) · Neoplasms, Vascular Tissue (91) · Neoplasms (84) · Neoplasms, Connective Tissue (57) · Neoplasms, Fibrous Tissue (55) · Neoplasms, Adipose Tissue (48) · Neoplasms, Muscle Tissue (47) · Neoplasms, Nerve Tissue (43) · Histiocytoma (39) · Nervous System Diseases (36) · Nervous System Neoplasms (36) · Peripheral Nervous System Neoplasms (36) · Neurofibroma (35) · Neuromuscular Diseases (35)
Doxorubicin (18) · Ifosfamide (13) · Radiotherapy (8) · Paclitaxel (7) · pazopanib (6) · Bevacizumab (4) · Chemotherapy, Adjuvant (4) · Filgrastim (4) · Gemcitabine (4) · pembrolizumab (4) · Carboplatin (3) · Docetaxel (3) · Epirubicin (3) · Etoposide (3) · Imatinib Mesylate (3)
European Organisation for Research and Treatment of Cancer - EORTC (14) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (4) · Centre Oscar Lambret (3) · Children's Oncology Group (3) · Memorial Sloan Kettering Cancer Center (3) · Agenus Inc. (2) · Brown University (2) · Northwestern University (2) · OHSU Knight Cancer Institute (2) · Societe Internationale d'Oncologie Pediatrique (2) · Tracon Pharmaceuticals Inc. (2) · Valerio Therapeutics (2) · Alliance for Clinical Trials in Oncology (1) · Angiex, Inc. (1)
United States (44) · France (18) · United Kingdom (17) · Belgium (11) · Denmark (11) · Germany (11) · Netherlands (10) · Spain (9) · Canada (7) · Austria (6) · Italy (5) · Slovakia (5) · Poland (4) · Sweden (4) · Switzerland (4)
Charles Theuer, MD (2) · A.N. Van Geel, MD (1) · Aaron H. Wolfson, MD (1) · Alba Rubio (1) · Amalya Sargsyan, MD (1) · Andrea Ferrari, MD (1) · Annabel B.M. Foot (1) · Antonio Casado (1) · Axel Le Cesne, MD (1) · Bernadette Brennan, MD (1) · Bradley D DeNardo, MD (1)
PMID 19451433, PMID 31401903, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 17634494, PMID 18809609, PMID 19088049, PMID 19451429, PMID 20338746, PMID 20434400, PMID 20471824, PMID 21796368, PMID 22198468, PMID 22285963, PMID 22623692, PMID 22649152, PMID 22665534, PMID 22954508, PMID 24005614, PMID 24215845, PMID 24218035, PMID 24618336, PMID 24747207, PMID 25858498, PMID 27406346, PMID 27406347, PMID 28391003, PMID 28851423, PMID 29450452, PMID 30305054, PMID 30357394, PMID 30954717, PMID 31786124, PMID 31969335, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 32941794, PMID 33203665, PMID 33362722
P30CA008748 (3), 2009 (2), N01CM62206 (2), U10CA098543 (2), 2015 (1), N01CM00071 (1), N01CM62201 (1), P30CA006927 (1), P30CA012197 (1), P30CA014599 (1), P30CA016672 (1), P30CA060553 (1), U01CA069856 (1), U10CA031946 (1), U10CA032102 (1)